Compliance copilot
Higher leverage · 2 cases · 2 scored
Directional evidence
Industry domain insight
This view tracks 58 documented AI deployments. Drug discovery is the most common use-case type with 13 cases, most often reporting a median −70% cost savings (n=5 metrics — early evidence); Drug discovery is growing fastest.
Executive brief
Drug discovery is 52× more concentrated here than across AI overall. Deployments of this type report a median −70% cost savings (n=5 metrics — early evidence).
Cases
58
14 in the last 6 months
Innovativeness
100% of evidence scored
Cases trend
Start here: Drug discovery — the strongest impact-for-effort balance among scored types (13 cases).
Relative leverage
2 of 9 scored types sit in the higher-leverage area; Compliance copilot is an early signal based on 2 scored cases; Therapeutics research (3 cases) is the largest high-impact investment signal.
Use-case types
Hover to highlight · Click to openTap a type to open
Compliance copilot
Higher leverage · 2 cases · 2 scored
Directional evidence
Patient engagement
Higher leverage · 4 cases · 4 scored
Directional evidence
Therapeutics research
High-impact investments · 3 cases · 3 scored
Directional evidence
Risk assessment
High-impact investments · 2 cases · 2 scored
Directional evidence
Drug discovery
Review trade-offs · 13 cases · 13 scored
Therapeutics discovery
Review trade-offs · 2 cases · 2 scored
Directional evidence
Legal document automation
Efficient extensions · 2 cases · 2 scored
Directional evidence
Life sciences innovation
Efficient extensions · 10 cases · 10 scored
Medical document automation
Efficient extensions · 2 cases · 2 scored
Directional evidence
Each dot is one Pharma Research & Development use-case type, sitting at the mean build effort and business impact of its scored cases, positioned relative to the other scored types shown. The dashed crosshair is the peer median, so the split compares leverage within this view.
The dashed indigo zone marks higher leverage: above-median impact for at-or-below-median effort. Dot size reflects scored cases; impact and effort figures in the list are the true 1–5 averages.
The use-case types deployed most often in this view, ranked by volume and coloured by recent momentum.
20 use-case types in view; Drug discovery leads with 13 cases, and 10 of the 40 cases shown were published in the last 6 months. 5 more types have a single case each and are not charted.
Drug discovery
Accelerates drug discovery by predicting promising molecules and targets.
Life sciences innovation
Applies AI across life-sciences R&D to speed discovery and development.
Patient engagement
Helps care providers reach and support patients with reminders, guidance, and personalized communication.
Therapeutics research
AI applied to therapeutics research.
Compliance copilot
Automates regulatory checks and reporting so processes stay compliant with far less manual review.
Legal document automation
Drafts, reviews, and processes legal documents automatically to speed up legal work.
Medical document automation
Automates creation and processing of medical records and documentation to save clinician time.
Risk assessment
Scores and prioritizes risk from data to support faster, more consistent decisions.
Therapeutics discovery
AI applied to therapeutics discovery.
The use-case types this view over-indexes on versus the whole corpus — what makes this slice different from AI overall.
Drug discovery is 51× more common here than across all cases — the strongest signal of what sets this view apart.
1× = corpus average · points show how many times more common each type is here.
Lift compares each type's share of this view against its share of all 3,431 cases. 51 of the 58 cases here are type-classified.
How the documented deployments in this view were built — custom engineering (Build), an off-the-shelf assistant (Buy), or low-code assembly (Compose).
Full report
Expand any section for the detail behind the summary above.
Reported outcomes: Drug discovery — median −70% cost savings across 5 metrics (early evidence). Expand for the full ladder and qualitative themes.
Reported challenge examples: Complexity and long timelines in drug discovery and development (3 cases), Complex and time-consuming drug discovery processes (2 cases), Traditional drug discovery is slow and costly, often taking 10-15 years to bring a new therapy to market (2 cases), A single-agent architecture became hard to scale because of intent ambiguity, module coupling, and parallel task scheduling complexity (1 case), and Accelerating AI adoption for scientific discovery is constrained by lack of harmonized, AI-ready data (1 case). Evidence is still limited; expand to inspect the source cases.
Gaining momentum: Drug discovery. Expand for the adoption curve and news signal.
Questions answered here:
Featured cases: